Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olanzapine/samidorphan - Alkermes plc

Drug Profile

Olanzapine/samidorphan - Alkermes plc

Alternative Names: ALKS 33/olanzapine; ALKS-3831; Olanzapine/ALKS 33; Samidorphan/olanzapine

Latest Information Update: 21 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alkermes plc
  • Class Amides; Antipsychotics; Benzodiazepines; Cyclopropanes; Morphinans; Oxazepines; Phenanthrenes; Small molecules; Thiazepines
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Opioid mu receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Bipolar disorders; Schizophrenia
  • Phase III Psychotic disorders

Most Recent Events

  • 19 Nov 2019 Preregistration for Bipolar disorders in USA (PO)
  • 19 Nov 2019 Preregistration for Schizophrenia in USA (PO)
  • 17 Oct 2019 Alkermes completes a phase III extension trial for Schizophrenia in Puerto Rico and USA (PO) (NCT02873208)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top